Followers | 3350 |
Posts | 86115 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Saturday, June 27, 2020 12:16:47 AM
June 26, 2020 04:05 PM Eastern Daylight Time
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on June 24, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 1,000 shares of its common stock to 2 new employees under Xeris’ Inducement Equity Plan.
Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter, and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. The non-qualified stock options are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke™. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.
Contacts
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Recent XERS News
- Xeris to Participate in Upcoming Investor Conferences • Business Wire • 08/22/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:06:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:27:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:15:47 AM
- Xeris Biopharma Reports Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:22:39 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:14:16 PM
- Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 • Business Wire • 07/25/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:14:32 AM
- Xeris Biopharma Announces CEO Succession Plan • Business Wire • 07/08/2024 11:00:00 AM
- Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 05:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:19:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:15:27 PM
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024 • Business Wire • 06/03/2024 11:00:00 AM
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) • Business Wire • 05/30/2024 11:30:00 AM
- Xeris to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:14:33 AM
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events • Business Wire • 05/09/2024 11:00:00 AM
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics • Business Wire • 05/06/2024 11:00:00 AM
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 05/02/2024 11:00:00 AM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 08:05:00 PM
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/02/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:10:13 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM